RxDoctor Payments Data

Charles Traube, MD

Cardiovascular Disease · Brooklyn, NYNPI 1316044274

Payments from drug & device makers

$1,117in general payments, 2019–2025

Across 59 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$136
  • Merck$102
  • Boehringer Ingelheim$94
  • E.r. Squibb & Sons, L.L.C.$87
  • GSK$76
  • AstraZeneca$72
  • plus $550 from 21 others

What the payments were for

  • Food & beverage$1,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,117 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$446,580
Medicare patients
807
Services billed
11,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$327,813
XareltoRivaroxaban96$116,567
EntrestoSacubitril/Valsartan45$60,776
JardianceEmpagliflozin40$53,369
JanuviaSitagliptin Phosphate28$29,369
FarxigaDapagliflozin Propanediol20$26,482
JanumetSitagliptin Phos/Metformin Hcl12$15,322
BrilintaTicagrelor11$14,113
Metoprolol Succinate573$8,871
Atorvastatin Calcium903$8,381
Losartan Potassium637$6,953
Breo ElliptaFluticasone/Vilanterol12$5,407
Rosuvastatin Calcium254$3,868
Amlodipine Besylate647$3,763
Simvastatin357$3,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$136$327,813287 claims
Johnson & JohnsonXarelto$38$116,56796 claims
Boehringer IngelheimJardiance$94$53,36940 claims
MerckJanuvia, Janumet$102$44,69140 claims
AstraZenecaFarxiga, Brilinta$72$40,59531 claims
GSKBreo Ellipta$76$5,40712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →